Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABVC
Nasdaq
8731
https://abvcpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ABVC Biopharma Inc
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
- Mar 26th, 2024 12:35 pm
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
- Mar 21st, 2024 12:30 pm
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
- Mar 19th, 2024 12:34 pm
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
- Mar 14th, 2024 1:34 pm
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
- Feb 27th, 2024 1:30 pm
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
- Feb 15th, 2024 1:30 pm
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
- Feb 12th, 2024 1:30 pm
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
- Feb 8th, 2024 2:22 pm
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
- Jan 3rd, 2024 12:24 pm
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
- Dec 7th, 2023 1:30 pm
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
- Dec 5th, 2023 1:30 pm
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
- Nov 21st, 2023 1:30 pm
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
- Nov 16th, 2023 3:05 pm
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
- Nov 15th, 2023 2:00 pm
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
- Oct 26th, 2023 12:30 pm
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
- Oct 17th, 2023 12:30 pm
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
- Oct 9th, 2023 12:30 pm
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
- Aug 23rd, 2023 12:30 pm
ABVC Executes Cooperation Agreement for Strategic Investments
- Aug 17th, 2023 1:19 pm
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
- Aug 10th, 2023 12:30 pm
Scroll